Interim report for Diamyd® directly into the lymph node indicates positive clinical course
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) today announced that the second interim report from DIAGNODE-1, an open clinical pilot study where the diabetes vaccine Diamyd® is administered directly into the lymph node, preliminary shows that the treatment after 15 months appears to be safe and tolerable and that the clinical progression in patients is positive in terms of the body’s own capacity to produce insulin, as well as long-term blood sugar and insulin dose. This preliminary evaluation will be presented by Professor Johnny Ludvigsson, principal investigator and sponsor of the